The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | ELEVATE-TN: approval of acalabrutinib for adult CLL
Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR, discusses the interim results for the phase III ELEVATE-TN study (NCT02475681), which evaluated the efficacy and safety of acalabrutinib combined with obinutuzumab or alone versus obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL). The results showed that both acalabrutinib combined with obinutuzumab and acalabrutinib monotherapy significantly improved progression-free survival, with tolerable safety. Dr Sharman highlights the recent approval of acalabrutinib for adults with CLL or small lymphocytic lymphoma (SLL) in the United States. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
